hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06306105, orgStudyIdInfo id: 23-118-B, briefTitle: Assessment of Anti-aging Efficacy of Marine Collagen Peptides, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: TCI Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To assess the anti-aging efficacy of Marine Collagen Peptides on skin, hair and finger nails for human, conditionsModule conditions: Skin Condition, conditions: Hair Fragility, conditions: Nails, Ingrown, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Marine Collagen Peptides, interventions name: placebo drink, outcomesModule primaryOutcomes measure: The change of skin hydation, primaryOutcomes measure: The change of skin wrinkles, primaryOutcomes measure: The change of skin elasticity, primaryOutcomes measure: The change of skin collagen density, primaryOutcomes measure: The change of hair diameters, primaryOutcomes measure: The change of hair loss amount, primaryOutcomes measure: The change of hair roots diameters, primaryOutcomes measure: The change of hair density, primaryOutcomes measure: The change of hair follicle strength, primaryOutcomes measure: The change of thumbs nail color, primaryOutcomes measure: The change of nails appearence, primaryOutcomes measure: The change of nails growth, primaryOutcomes measure: The degree of nails fragility, secondaryOutcomes measure: The change of self-assessment skin, hair, and nails condition, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chia Nan University of Pharmacy & Science, status: RECRUITING, city: Pingtung, zip: 928, country: Taiwan, contacts name: Chia-Hua Liang, role: CONTACT, phone: +886-06-2664911, phoneExt: 2441, email: tinna_ling@mail.cnu.edu.tw, contacts name: Ping Lin, role: CONTACT, phone: +886-02-879778111, email: candice.lin@tci-bio.com, geoPoint lat: 22.67135, lon: 120.48814, hasResults: False
protocolSection identificationModule nctId: NCT06306092, orgStudyIdInfo id: 2023-02885-01, briefTitle: Promoting Teenage Sleep for Improved Mental Health and School Performance, acronym: TeenSleep, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2028-06, completionDateStruct date: 2030-06, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Kristianstad University, class: OTHER, collaborators name: Karolinska Institutet, collaborators name: Örebro University, Sweden, collaborators name: Academic Primary Health Care Centre, Region Stockholm, descriptionModule briefSummary: The overall aim of this project is to evaluate the effectiveness of two school-based programs that have the potential to promote adolescent sleep and prevent future depressive symptoms. The programs will be offered to students aged 13-19 at Swedish high schools and upper secondary schools at the classroom level. The students will be compared to teaching as usual (control group)., conditionsModule conditions: Mental Health Issue, conditions: Insomnia, conditions: Depression, conditions: Anxiety, conditions: Daytime Sleepiness, conditions: Wellness, Psychological, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 3000, type: ESTIMATED, armsInterventionsModule interventions name: Sleep on Schedule, interventions name: Technology restriction, outcomesModule primaryOutcomes measure: Change in sleep duration, hours and minutes, secondaryOutcomes measure: Change in Hospital Anxiety and Depression Scale scores, secondaryOutcomes measure: Change in Adolescent Sleep Hygiene Scale scores, secondaryOutcomes measure: Change in Insomnia Severity Index score, secondaryOutcomes measure: Change in EuroQol Visual Analog Scale (EQ VAS) score, secondaryOutcomes measure: Change in CHU9D Child Health Utility 9D (CHU9D) scores, secondaryOutcomes measure: Change in Sleep knowledge, secondaryOutcomes measure: Change in electronic media use, secondaryOutcomes measure: Change in sleep habits, secondaryOutcomes measure: Change in meta-cognitions, secondaryOutcomes measure: Change in motivation, eligibilityModule sex: ALL, minimumAge: 13 Years, maximumAge: 19 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2024-02-23, uploadDate: 2024-03-07T03:17, filename: Prot_SAP_000.pdf, size: 264890, hasResults: False
protocolSection identificationModule nctId: NCT06306066, orgStudyIdInfo id: 2015/962-31, briefTitle: Coronary Thermo-dilution Derived Flow-indices in Chronic Coronary Syndrome, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-09-02, primaryCompletionDateStruct date: 2021-06-07, completionDateStruct date: 2022-12-28, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, collaborators name: Abbott, descriptionModule briefSummary: Patients scheduled for elective coronary angiography due to chronic coronary syndrome are recruited at admission to hospital before the coronary anatomy is known. Immediately after coronary angiography measures thermo-dilution derived flow indices are obtained in the left left anterior descending artery (LAD). The patients are followed through telephone-calls and medical records at 1 and 2 years after inclusion and at completion of the study. The hypothesis is that elevated index of microcirculatory resistance (IMR),(\>25) is associated with all-cause death, myocardial infarction (MI) and hospitalization due to congestive heart failure (CHF).The primary analysis is the relationship between IMR and the composite outcome all-cause death, MI and hospitalization due to CHF., conditionsModule conditions: Coronary Artery Disease, conditions: Microvascular Angina, conditions: Coronary Microvascular Dysfunction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 505, type: ACTUAL, outcomesModule primaryOutcomes measure: Rate of all-cause mortality, MI and/or hospitalization due to CHF, secondaryOutcomes measure: Rate of all-cause mortality, secondaryOutcomes measure: Rate of hospitalization due to CHF., secondaryOutcomes measure: Rate of all-cause mortality and/or MI, secondaryOutcomes measure: Rate of MI, secondaryOutcomes measure: Rate of stroke, secondaryOutcomes measure: Rate of ischemic stroke, secondaryOutcomes measure: Rate of unscheduled revascularization, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Danderyd University Hospital and Karolinska Institutet Danderyds University Hospital (KI DS), city: Stockholm, zip: 182 88, country: Sweden, geoPoint lat: 59.33258, lon: 18.0649, hasResults: False
protocolSection identificationModule nctId: NCT06306040, orgStudyIdInfo id: Analgesia effect as on EA, briefTitle: Effect of Intravenous Nalbuphine and Magnesium Sulfate on Emergence Agitation in Pediatric, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2024-11-03, completionDateStruct date: 2025-01-30, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: • Primary outcome: Measure The incidence of EA in children undergoing to hypospadias repair under general anesthesia is considered using Pediatric Anesthesia Emergence Delirium (PAED) scales.• Secondary outcome:* Therefore, we designed a prospective, randomized, double-blind, single center study to investigate whether nalbuphine and/or magnesium sulphate can prevent EA after hypospadias repair in children under general anesthesia. In addition, the characteristics of anesthesia recovery and the incidence of adverse effects will also be evaluated in this study. Post-operative extubating time, interaction time, open eye time and emergence time. incidence of post-operative vomiting (PONV), laryngospasm, breath-holding, coughing, oxygen desaturation, and cardiac arrhythmias.* Face, Legs, Activity, Cry and Consola Bility (FLACC) scale is used to determine post-operative pain score* Parental satisfaction scores, conditionsModule conditions: Emergence Delirium, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: * Group C (Control group n=35 ): 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery* Group M (Magnesium sulfate group n=35 ): 30 mg/kg Magnesium sulphate diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery* Group N (Nalbuphine group n=35 ): 0.1 mg/kg nalbuphine diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, maskingDescription: * Group C (Control group n=35 ): 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery* Group M (Magnesium sulfate group n=35 ): 30 mg/kg Magnesium sulphate diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery* Group N (Nalbuphine group n=35 ): 0.1 mg/kg nalbuphine diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery, whoMasked: PARTICIPANT, enrollmentInfo count: 105, type: ESTIMATED, armsInterventionsModule interventions name: Nalbuphine Versus Magnesium Sulfate, outcomesModule primaryOutcomes measure: compare between analgesia effect on pediatric patient, eligibilityModule sex: MALE, minimumAge: 3 Years, maximumAge: 7 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06305988, orgStudyIdInfo id: LYG2023021, briefTitle: Neuroregulatory Effect and Mechanism of tDCS on Medial Prefrontal Cortex in ASD, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-01, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Jian-Jun Ou, class: OTHER, descriptionModule briefSummary: In this proposed study, a transcranial direct current stimulator is used to intervene in the medial prefrontal cortex of children with autism, and the efficacy of this intervention method is evaluated, as well as the internal mechanism of Autism Spectrum Disorders' intervention is discussed., conditionsModule conditions: ASD, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Transcranial direct current stimulation, outcomesModule primaryOutcomes measure: Autism assessment assessment index, secondaryOutcomes measure: EEG physiological detection index, secondaryOutcomes measure: Social Communication Changes index, secondaryOutcomes measure: Stereotyped behavior index, secondaryOutcomes measure: Sensory index, secondaryOutcomes measure: Abnormal behavior indicator, secondaryOutcomes measure: Sleep index, otherOutcomes measure: Plasma Metabolite Levels Assessment, otherOutcomes measure: Safety evaluation SAFTEE indicator, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Department of Psychiatry, Xiangya Second Hospital, Central South University, status: RECRUITING, city: Changsha, state: Hunan, zip: 410000, country: China, contacts name: Jianjun Ou, doctor, role: CONTACT, phone: 17775861486, email: oujianjun@csu.edu.cn, geoPoint lat: 28.19874, lon: 112.97087, hasResults: False
protocolSection identificationModule nctId: NCT06305975, orgStudyIdInfo id: STUDY00003169, briefTitle: Blunt Fascial vs. Veress Needle Peritoneal Entry in Laparoscopic Gynecologic Surgery, acronym: BluntFascial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Cedars-Sinai Medical Center, class: OTHER, descriptionModule briefSummary: This study aims to investigate the effect of two peritoneal entry techniques on intraoperative and post-operative outcomes among patients undergoing laparoscopic surgery with a minimally invasive gynecologic surgeon. Patients will be randomized to either blunt fascial or veress needle peritoneal entry. Insufflation times, failed entries, complications and post-operative pain scores will be collected.The investigators hypothesize that the blunt entry technique will be associated with shorter insufflation times and similar intraoperative and postoperative outcomes compared with the veress needle entry technique.Primary Objective: To evaluate the insufflation times and success upon peritoneal entry according to peritoneal entry technique.Secondary Objectives: To evaluate the surgical outcomes and patients pain scores according to peritoneal entry technique., conditionsModule conditions: Laparoscopic Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Blunt fascial abdominal entry, interventions name: Veress needle abdominal entry, outcomesModule primaryOutcomes measure: Insufflation time, primaryOutcomes measure: Success upon peritoneal entry, secondaryOutcomes measure: Intraoperative complications, secondaryOutcomes measure: Postoperative complications, secondaryOutcomes measure: Patients pain scores, secondaryOutcomes measure: Analgesics use, secondaryOutcomes measure: Length of hospital stay, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06305949, orgStudyIdInfo id: XC23DDDS0098, briefTitle: Clinical Trial on the Safety and Efficacy of Optimized Transcranial Direct Current Stimulation for the Swallowing Function in Patients With Post-Stroke Dysphagia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-07-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: NEUROPHET, class: INDUSTRY, collaborators name: Bucheon St. Mary's Hospital, collaborators name: Saint Vincent's Hospital, Korea, collaborators name: National Traffic Injury Rehabilitation Hospital, collaborators name: Pusan National University Yangsan Hospital, descriptionModule briefSummary: The goal of this clinical trial is to evaluate whether the application of optimized transcranial direct current stimulation is more effective compared to sham stimulation for temporary improvement of swallowing function in patients with post-stroke dysphagia., conditionsModule conditions: Deglutition Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Personalized transcranial Direct Current Stimulation, outcomesModule primaryOutcomes measure: Functional Oral Intake Scale (FOIS), primaryOutcomes measure: Penetration-aspiration Scale (PAS), secondaryOutcomes measure: Functional Oral Intake Scale (FOIS), secondaryOutcomes measure: Penetration-aspiration Scale (PAS), secondaryOutcomes measure: Videofluoroscopic Dysphagia Scale (VDS), secondaryOutcomes measure: Korean Mann Assessment of Swallowing Ability (K-MASA), secondaryOutcomes measure: Speech Mechanism Screening Test (SMST), secondaryOutcomes measure: Urimal Test of Articulation and Phonology (U-TAP), secondaryOutcomes measure: modified Rankin Scale (mRS), secondaryOutcomes measure: Gugging Swallowing Screen, secondaryOutcomes measure: Eating Assessment Tool-10 (EAT-10), secondaryOutcomes measure: Iowa Oral Performance Instrument (IOPI), secondaryOutcomes measure: Motor-Evoked Potential (MEP), secondaryOutcomes measure: Grade, Roughness, Breathiness, Asthenia and Strain scale(GRBAS scale), secondaryOutcomes measure: Respiratory muscle strength, secondaryOutcomes measure: Peak cough flow, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06305923, orgStudyIdInfo id: RNN/275/21/KE, secondaryIdInfos id: 503/3-066-02/503-31-001, type: OTHER_GRANT, domain: Medical University of Lodz, briefTitle: The Efficacy of a Cosmetic Preparation Containing Sheep Colostrum on Mature Skin, acronym: COLMATSKIN, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2022-06-30, completionDateStruct date: 2022-07-31, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Medical University of Lodz, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn about colostrum as a cosmetic in mature skin. . The aim of the study was to examine the effect of a cosmetic preparation containing sheep colostrum on skin with signs of aging in mature women Participants will be given the creams and asked to apply one -two doses in the evening after nighttime facial cleaning. They were also asked to use sunscreens during the day. During the first visit and after eight weeks of everyday use of the tested cream, the skin parameters will be measured three times on both cheeks, and the results were averaged.Participants will be enrolled to the colostrum cream or base cream groups and will not be informed which group they belonged to., conditionsModule conditions: Skin Aging, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 52, type: ACTUAL, armsInterventionsModule interventions name: colostrum cream, interventions name: placebo cream, outcomesModule primaryOutcomes measure: hydration, primaryOutcomes measure: transepidermal water loss, primaryOutcomes measure: erythema and melanin content, primaryOutcomes measure: sebum, secondaryOutcomes measure: firmness of the skin, secondaryOutcomes measure: firmness of the skin, eligibilityModule sex: FEMALE, minimumAge: 40 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical University of Lodz, city: Lodz, zip: 90-419, country: Poland, geoPoint lat: 51.75, lon: 19.46667, hasResults: False
protocolSection identificationModule nctId: NCT06305910, orgStudyIdInfo id: CMN-DMGVac-01, briefTitle: CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-09-15, completionDateStruct date: 2027-01-15, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: OX2 Therapeutics, class: INDUSTRY, descriptionModule briefSummary: This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults.The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation therapy for newly diagnosed Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG)., conditionsModule conditions: Diffuse Midline Glioma, H3 K27M-Mutant, conditions: Recurrent High Grade Glioma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, interventionModelDescription: 3+3 design, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Treatment with CD200AR-L, outcomesModule primaryOutcomes measure: Maximum Tolerated Dose (MTD) of CD200AR-L, secondaryOutcomes measure: Incidence of serious adverse events (SAEs), secondaryOutcomes measure: Time to progression (TTP) by 24 months, secondaryOutcomes measure: Progression free survival (PFS) by 24 months, secondaryOutcomes measure: Overall survival (OS) by 24 months, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 25 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Children's Minnesota, status: RECRUITING, city: Minneapolis, state: Minnesota, zip: 55404, country: United States, contacts name: Anne Bendel, MD, role: CONTACT, phone: 612-813-5940, email: anne.bendel@childrensmn.org, geoPoint lat: 44.97997, lon: -93.26384, hasResults: False